Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 279.26% higher on its value in year-to-date trading and has touched a low of $1.89 and a high of $13.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $12.77 in the last trading session, with the day’s loss setting it -0.52%.
Currently trading at $12.25, the stock is 6.96% and 19.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.82 million and changing -4.07% at the moment leaves the stock 25.71% off its SMA200. ARQT registered 494.66% gain for a year compared to 6-month gain of 31.16%. The firm has a 50-day simple moving average (SMA 50) of $10.1696 and a 200-day simple moving average (SMA200) of $9.7356.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 19.51% loss in the last 1 month and extending the period to 3 months gives it a 14.92%, and is -0.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.23% over the week and 7.23% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 296 employees, a market worth around $1.43B and $138.71M in sales. Profit margin for the company is -140.97%. Distance from 52-week low is 548.15% and -9.26% from its 52-week high. The company has generated returns on investments over the last 12 months (-73.92%).
with sales reaching $54.67M over the same period.The EPS is expected to grow by 64.44% this year, but quarterly earnings will post 202.28% year-over-year. Quarterly sales are estimated to grow 304.18% in year-over-year returns.
261.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 116.10% of the company’s shares. The shares outstanding are 117.00M, and float is at 102.95M with Short Float at 22.85%. Institutions hold 113.61% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712 of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95 and valued at over $91.3 million, while BLACKROCK INC. holds 7.7647 of the shares totaling 8.62 million with a market value of $80.19 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider purchase by Edwards Larry Todd, the company’s. SEC filings show that Edwards Larry Todd bought 1,093 shares of the company’s common stock on Nov 30 ’24 at a price of $7.11 per share for a total of $7767.0. Following the purchase, the insider now owns 0.14 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Nov 30 ’24 that Matsuda Masaru () bought a total of 1,657 shares of the company’s common stock. The trade occurred on Nov 30 ’24 and was made at $7.11 per share for $11775.0. Following the transaction, the insider now directly holds 0.19 million shares of the ARQT stock.
Still, SEC filings show that on May 31 ’24, Matsuda Masaru () acquired 4,000 shares at an average price of $1.69 for $6768.0. The insider now directly holds 185,373 shares of Arcutis Biotherapeutics Inc (ARQT).
